CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple...
Phase 1, Phase 2
Atlanta, Georgia, United States and 1 other location
(SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC).The pri...
Phase 1, Phase 2
Atlanta, Georgia, United States and 15 other locations
maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast...
Phase 1
Atlanta, Georgia, United States and 7 other locations
biosimilar in Black and non-Black patients with metastatic triple negative and ER-positive, HER2-negative breast ....
Phase 2
Atlanta, Georgia, United States and 6 other locations
doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...
Phase 3
Duluth, Georgia, United States and 216 other locations
and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen rec...
Phase 2, Phase 3
Atlanta, Georgia, United States and 294 other locations
or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...
Phase 3
Atlanta, Georgia, United States and 376 other locations
This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is th...
Phase 1
Atlanta, Georgia, United States and 17 other locations
The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effec...
Phase 2
Atlanta, Georgia, United States and 9 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...
Phase 3
Atlanta, Georgia, United States and 374 other locations
Clinical trials
Research sites
Resources
Legal